End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.44 CAD | +3.53% | -2.22% | -37.14% |
Apr. 02 | Sernova Corp. Provides Positive Clinical and Platform Portfolio Update | CI |
Mar. 19 | Sernova Corp. Reports Earnings Results for the First Quarter Ended January 31, 2024 | CI |
Valuation
Fiscal Period: Oktober | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 38.15 | 55.19 | 326.4 | 234.5 | 243.9 | 133.5 | - | - |
Enterprise Value (EV) 1 | 38.15 | 55.19 | 326.4 | 234.5 | 235.1 | 109.9 | 115.8 | 133.5 |
P/E ratio | -9.75 x | -6.63 x | -41.7 x | -8.89 x | -5.85 x | -3.91 x | -3.74 x | -5.5 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - | 666 x |
EV / Revenue | - | - | - | - | - | - | - | 666 x |
EV / EBITDA | -9.67 x | -11 x | -48.9 x | -9.64 x | -5.87 x | -3.24 x | -3.47 x | -4.98 x |
EV / FCF | - | - | -46.2 x | -3.86 x | -7.72 x | 28.5 x | -3.75 x | - |
FCF Yield | - | - | -2.17% | -25.9% | -12.9% | 3.51% | -26.6% | - |
Price to Book | - | - | - | - | 18.4 x | 7.33 x | 11 x | - |
Nbr of stocks (in thousands) | 195,660 | 208,263 | 261,133 | 293,125 | 320,857 | 303,408 | - | - |
Reference price 2 | 0.1950 | 0.2650 | 1.250 | 0.8000 | 0.7600 | 0.4400 | 0.4400 | 0.4400 |
Announcement Date | 2/14/20 | 2/1/21 | 2/14/22 | 1/26/23 | 1/29/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: Oktober | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | 0.2003 |
EBITDA 1 | -3.947 | -5.035 | -6.669 | -24.31 | -40.06 | -33.93 | -33.36 | -26.81 |
EBIT 1 | - | - | -6.937 | -24.75 | -40.5 | -15.25 | -35.9 | -43.4 |
Operating Margin | - | - | - | - | - | - | - | -21,664.25% |
Earnings before Tax (EBT) 1 | -3.971 | -5.321 | -6.966 | -24.42 | -39 | -31.3 | -35.8 | -43.1 |
Net income 1 | -3.971 | -5.321 | -6.966 | -24.42 | -39 | -31.3 | -25.56 | -27.34 |
Net margin | - | - | - | - | - | - | - | -13,645.24% |
EPS 2 | -0.0200 | -0.0400 | -0.0300 | -0.0900 | -0.1300 | -0.1125 | -0.1175 | -0.0800 |
Free Cash Flow 1 | - | - | -7.073 | -60.76 | -30.44 | 3.861 | -30.84 | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 2/14/20 | 2/1/21 | 2/14/22 | 1/26/23 | 1/29/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: October | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | -2.373 | -5.363 | -4.822 | -5.794 | -8.334 | -8.501 | -9.699 | -10.16 | - | -9.923 | -7.7 | -7.1 | -5.8 | - | - |
EBIT | - | - | - | - | -8.452 | -8.608 | -9.808 | - | - | - | - | - | - | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | -5.831 | -8.21 | -8.015 | -9.347 | -9.932 | -11.7 | - | - | -9.336 | -9.988 | - | - |
Net income | - | - | - | -5.831 | -8.21 | -8.015 | -9.347 | -9.932 | -11.7 | - | - | -9.336 | -9.988 | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | - | -0.0200 | -0.0200 | -0.0200 | -0.0300 | -0.0300 | -0.0300 | -0.0300 | -0.0400 | -0.0300 | -0.0267 | -0.0300 | -0.0267 | -0.0300 | -0.0300 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 2/14/22 | 3/29/22 | 6/27/22 | 9/14/22 | 1/26/23 | 3/16/23 | 6/13/23 | 9/13/23 | 1/29/24 | 3/18/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: October | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - | - | - |
Net Cash position 1 | - | - | - | - | 8.72 | 23.6 | 17.7 | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | - | -7.07 | -60.8 | -30.4 | 3.86 | -30.8 | - |
ROE (net income / shareholders' equity) | - | - | - | - | -130% | - | -3,513% | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share 2 | - | - | - | - | 0.0400 | 0.0600 | 0.0400 | - |
Cash Flow per Share 2 | - | - | - | - | -0.1000 | -0.0700 | -0.0800 | -0.0900 |
Capex 1 | - | - | 0.23 | 46.3 | 0.1 | 0.03 | 0.1 | 0.04 |
Capex / Sales | - | - | - | - | - | - | - | 19.97% |
Announcement Date | 2/14/20 | 2/1/21 | 2/14/22 | 1/26/23 | 1/29/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.14% | 97.52M | |
+12.07% | 128B | |
-9.04% | 10.65B | |
+0.91% | 8.82B | |
+16.72% | 7.19B | |
+25.15% | 4.99B | |
+7.17% | 3.4B | |
-1.36% | 3.03B | |
-8.73% | 2.14B | |
-10.15% | 2B |
- Stock Market
- Equities
- SVA Stock
- Financials Sernova Corp.